Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Hims & Hers Health, Inc. Class A Common Stock (NY:HIMS)

45.46 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Hims & Hers Health, Inc. Class A Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
31 32 Next >
Hims & Hers Stock: Buy the Dip or Wait It Out?
Hims & Hers stock is giving up some gains after announcing the acquisition of Zava, a European digital healthcare platform. 
Via MarketBeat
Topics World Trade
Hims & Hers Goes on a Buying Spree
Hims & Hers is expanding into Europe in a global push the company previewed earlier this year. 
Via The Motley Fool
HIMS & HERS HEALTH INC (NYSE:HIMS) – A Strong Growth Stock Meeting Minervini’s Criteria
HIMS & HERS HEALTH INC (NYSE:HIMS) is a high-growth telehealth stock meeting Minervini’s Trend Template with strong earnings, revenue growth, and bullish technicals. 
Via Chartmill
Hims & Hers ZAVA Acquisition Deal Expands Its Market Opportunity By $52 Billion: Analyst
Hims & Hers is acquiring digital health provider ZAVA to expand into Europe, aiming to boost revenue and international market reach by 2026. 
Via Benzinga
Hims & Hers Health Stock: A Deep Dive Into Analyst Perspectives (10 Ratings)
 
Via Benzinga
Market Whales and Their Recent Bets on HIMS Options
 
Via Benzinga
Check Out What Whales Are Doing With HIMS
 
Via Benzinga
3 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
Unpacking the Latest Options Trading Trends in Hims & Hers Health
 
Via Benzinga
2 Incredible Growth Stocks to Buy Hand Over Fist
Via The Motley Fool
Topics Economy
3 Market-Beating Stocks Worth Your Attention
Companies that consistently increase their sales, margins, or returns on capital are usually rewarded with the best returns, and those that can do all three for years on end are almost always the... 
Via StockStory
These stocks are making the most noise in today's session.
Curious about the most active stocks in today's session? Get a glimpse into the stocks that are generating the highest trading volume and capturing market attention. 
Via Chartmill
EXCLUSIVE: May's 20 Most-Searched Tickers On Benzinga Pro — Where Do Apple, Palantir, CoreWeave, Nvidia Rank?
Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market and individual tickers. 
Via Benzinga
Hims & Hers To Acquire European Telehealth Brand Zava As It Looks To Expand Globally
The Zava acquisition will enable Hims & Hers to expand its footprint in the U.K. and launch operations in countries such as Germany, France, and Ireland, with other markets expected to follow soon. 
Via Stocktwits
Topics Government
Hims & Hers Health Stock Is Rising Tuesday: What's Going On?
Hims & Hers Health Inc (NYSE:HIMS) shares are trading higher Tuesday after the company announced an acceleration of its global expansion through the acquisition of ZAVA. 
Via Benzinga
IBD 50's Hims & Hers Health Shoots Higher On A Key Takeover In Europe
The company hopes the deal will help it snag business in the UK, building a similar model to its U.S. platform. 
Via Investor's Business Daily
Topics ETFs
1 Healthcare Stock Worth Your Attention and 2 to Turn Down
Personal health and wellness is one of the many secular tailwinds for healthcare companies. But speed bumps such as inventory destockings have persisted in the wake of COVID-19, and over the past six... 
Via StockStory
Topics Stocks
Hims & Hers Faces Retail Skepticism After Layoffs, FDA Ban on Compounded Wegovy
The company said the layoffs were unrelated to the regulatory change. 
Via Stocktwits
Topics Law Enforcement Workforce
Novo Nordisk Is Shedding Muscle In The Weight-Loss Brawl With Eli Lilly
Eli Lilly is rapidly encroaching on Novo Nordisk's yearslong lead in GLP-1 drugs. Can Novo hold its tentpole position? 
Via Investor's Business Daily
3 Surprising Stocks That Have More Than Doubled in 2025
Just 14 stocks with market caps above $1 billion have doubled so far this year. They probably aren't the winners you would have predicted. 
Via The Motley Fool
Topics Government
Super Micro Computer, Hims & Hers And Aurora Innovation Are Among Top 10 Large-Cap Losers Last Week (May 19-May 23): Are The Others In Your Portfolio?
Large-cap stocks were the worst performers last week, with declines up to 23%. Reasons include revenue misses, FDA bans, and Uber's stake monetization. 
Via Benzinga
Benzinga Bulls And Bears: Alphabet, L3Harris, Target — And Latest Tariff News Roils Markets
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories. 
Via Benzinga
MarketBeat Week in Review – 05/19 - 05/23
Stocks were moving lower to end the week as tariff concerns returned; however NVIDIA earnings next week may help investors climb the wall of worry 
Via MarketBeat
Topics Artificial Intelligence Bonds Economy
8 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
Why Hims & Hers Health (HIMS) Stock Is Falling Today
Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 6.3% in the afternoon session after Cigna Group's Evernorth division introduced a monthly $200 price cap for weight-loss medications... 
Via StockStory
Topics Artificial Intelligence
Will Hims & Hers Stock Be Okay After UnitedHealth's Sell-Off?
The UnitedHealth stock sell-off might have spooked investors in the medical sector, who are wondering if it will affect shares of Hims & Hers equally. 
Via MarketBeat
Topics Government World Trade
Hims & Hers Stock Drops After Evernorth Announces Cheaper Pricing For Weight-Loss Drugs: Retail’s Dull
Truist noted on Thursday that the $200/month price point is "highly attractive compared to other price points in the market," including Hims & Hers' compounded Semaglutide, Wegovy, and Liraglutide... 
Via Stocktwits
Hims & Hers Health Stock Is Tumbling Thursday: What's Happening?
Hims & Hers Health, Inc (NYSE:HIMS) is facing heavy selling pressure Thursday morning as the U.S. Food and Drug Administration's (FDA) ban of compounded drugs with semaglutide takes effect. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
Up 157% in 2025, Is It Too Late to Buy Hims & Hers Stock?
Via The Motley Fool
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
31 32 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback